Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
For most lysosomal storage diseases (LSDs) affecting the CNS, there is currently no cure. The BBB, which limits the bioavailability of drugs administered systemically, and the short half-life of lysosomal enzymes, hamper the development of effective therapies. Mucopolysaccharidosis type IIIA (MPS IIIA) is an autosomic recessive LSD caused by a deficiency in sulfamidase, a sulfatase involved in the stepwise degradation of glycosaminoglycan (GAG) heparan sulfate. Here, we demonstrate that intracerebrospinal fluid (intra-CSF) administration of serotype 9 adenoassociated viral vectors (AAV9s) encoding sulfamidase corrects both CNS and somatic pathology in MPS IIIA mice. Following vector administration, enzymatic activity increased throughout the brain and in serum, leading to whole body correction of GAG accumulation and lysosomal pathology, normalization of behavioral deficits, and prolonged survival. To test this strategy in a larger animal, we treated beagle dogs using intracisternal or intracerebroventricular delivery. Administration of sulfamidase-encoding AAV9 resulted in transgenic expression throughout the CNS and liver and increased sulfamidase activity in CSF. High-titer serum antibodies against AAV9 only partially blocked CSF-mediated gene transfer to the brains of dogs. Consistently, anti-AAV antibody titers were lower in CSF than in serum collected from healthy and MPS IIIA-affected children. These results support the clinical translation of this approach for the treatment of MPS IIIA and other LSDs with CNS involvement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, direct delivery of AAV to the CNS was well tolerated in animal models [185, 186].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [185]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 5×
“…systemically may be neutralized by anti-AAV antibodies (42–44), which are highly prevalent in humans (41); finally, systemic exposure to high doses of AAV vectors may trigger the activation of CD8 + T cell responses directed against the viral capsid in a dose-dependent manner (16, 42, 50, 51).”
InfluentialSelf-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 1×
“Lentiviral vector–mediated transduction of autologous CD34+ HSCs has shown therapeutic efficacy in adrenoleukodystrophy (12), and Authorship note: Virginia Haurigot and Sara Marcó contributed equally to this work.”
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 12×
“Asymmetrical distribution of AAV-neutralizing antibodies across the BBB .”
InfluentialClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 1×
“Alternatively, AAV9, a serotype recently isolated from human tissue (25), has been shown to have broad tropism and to cross the BBB after systemic administration (26, 27), reverting the neurological phenotype of MPS IIIB (28) and MPS IIIA (29) mice.”
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 4×
“…serum NAb titers greater than 1:1,000) and given that only a small proportion of humans will present with very high anti-AAV9 antibody titers (41), GFP expression was detected throughout the CNS, particularly in the leptome-ninges in both injected animals (Figure 11, A and B), though at what…”
InfluentialTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893 · cited 2×
“In vivo gene therapy offers the possibility of a one-time treat-ment for MPS IIIA and other inherited diseases, with the prospect of lifelong beneficial effects (14).”
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 1×
“…systemically may be neutralized by anti-AAV antibodies (42–44), which are highly prevalent in humans (41); finally, systemic exposure to high doses of AAV vectors may trigger the activation of CD8 + T cell responses directed against the viral capsid in a dose-dependent manner (16, 42, 50, 51).”
Self-citationInagaki, K., Fuess, S., Storm, T. A., Gibson, G. A., Mctiernan, C. F., Kay, M. A., & Nakai, H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.014 · Cited by 610 · cited 1×
“Additionally, AAV9 vectors delivered into the bloodstream efficiently transduce several peripheral tissues, such as liver, heart, and skeletal muscle, demonstrating a broad distribution profile (27, 32).”
Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.-M., Fyfe, J., Moullier, P., Colle, M.-A., & Barkats, M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.71 · Cited by 511 · cited 4×
“Additionally, AAV9 vectors delivered into the bloodstream efficiently transduce several peripheral tissues, such as liver, heart, and skeletal muscle, demonstrating a broad distribution profile (27, 32).”
Influential
Research works printed but not linked: 1
- Hemsley, 2009, Int J Clin Pharmacol Ther., 47, S118
Cited by
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Self-citationAAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Self-citationTherapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 369
FGF21 gene therapy as treatment for obesity and insulin resistance
Jimenez, V., Jambrina, C., Casana, E., Sacristan, V., Muñoz, S., Darriba, S., Rodó, J., Mallol, C., Garcia, M., León, X., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708791 · Cited by 324
“The open-field test was performed between 9:00 am and 1:00 pm as previously reported (Haurigot et al, 2013).”
MethodSelf-citationGene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.110 · Cited by 306
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291
“Potential additional positive effects of this approach on the non-CNS pathology have been observed but only in the absence of serum antibodies against the vector.(49) Intracisternal administration, although easily accessible in animal models, is more problematic to translate into humans.”
BackgroundTardieu, M., Zérah, M., Husson, B., de Bournonville, S., Deiva, K., Adamsbaum, C., Vincent, F., Hocquemiller, M., Broissand, C., Furlan, V., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.238 · Cited by 261
“…routes of injection, including the administration of AAV2/9 encoding SGSH via the CSF or systemically and liver gene transfer with an AAV2/8 encoding an engineered sulfamidase that efficiently crosses the blood–brain barrier (Ruzo et al., 2012; Haurigot et al., 2013; Sorrentino et al., 2013).”
BackgroundMethodInfluentialErratum: Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.158 · Cited by 248
Mingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206
Self-citationGene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9
Saraiva, J., Nobre, R. J., & Pereira de Almeida, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.011 · Cited by 201
Schuster, D. J., Dykstra, J. A., Riedl, M. S., Kitto, K. F., Belur, L. R., McIvor, R. S., Elde, R. P., Fairbanks, C. A., & Vulchanova, L. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00042 · Cited by 161
“ORIGINAL RESEARCH ARTICLE published: 10 June 2014 doi: 10.3389/fnana.2014.00042 Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse”
BackgroundMethodResultInfluentialImmunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“In addition, direct delivery of AAV to the CNS was well tolerated in animal models [185, 186].”
BackgroundLiguore, W. A., Domire, J. S., Button, D., Wang, Y., Dufour, B. D., Srinivasan, S., & McBride, J. L. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.07.017 · Cited by 150
Arrant, A. E., Onyilo, V. C., Unger, D. E., & Roberson, E. D. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.3081-17.2018 · Cited by 156
“Prior studies have shown that immune responses to AAV transgenes can suppress expression of the AAV transgene, although therapeutic benefits may still be observed (Yuasa et al., 2007; Mendell et al., 2010; Haurigot et al., 2013).”
BackgroundA large animal model of spinal muscular atrophy and correction of phenotype
Duque, S. I., Arnold, W. D., Odermatt, P., Li, X., Porensky, P. N., Schmelzer, L., Meyer, K., Kolb, S. J., Schümperli, D., Kaspar, B. K., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24332 · Cited by 135
Long-lasting analgesia via targeted in situ repression of Na V 1.7 in mice
Moreno, A. M., Alemán, F., Catroli, G. F., Hunt, M., Hu, M., Dailamy, A., Pla, A., Woller, S. A., Palmer, N., Parekh, U., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aay9056 · Cited by 135
Recent progress and considerations for AAV gene therapies targeting the central nervous system
Lykken, E. A., Shyng, C., Edwards, R. J., Rozenberg, A., & Gray, S. J. (2018) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-018-9234-0 · Cited by 143
“Intravenous administration of AAV9 expressing heparan N-sulfatase in the MPS3A mouse model achieves whole body correction of GAG accumulation and significantly prolongs lifespan [59, 60].”
BackgroundAdeno-Associated Virus Vectors and Neurological Gene Therapy
Ojala, D. S., Amara, D. P., & Schaffer, D. V. (2015) · The Neuroscientist · doi:10.1177/1073858414521870 · Cited by 136
Samaranch, L., Sebastian, W. S., Kells, A. P., Salegio, E. A., Heller, G., Bringas, J. R., Pivirotto, P., DeArmond, S., Forsayeth, J., & Bankiewicz, K. S. (2014) · Molecular Therapy · doi:10.1038/mt.2013.266 · Cited by 142
Hinderer, C., Bell, P., Katz, N., Vite, C. H., Louboutin, J.-P., Bote, E., Yu, H., Zhu, Y., Casal, M. L., Bagel, J., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.026 · Cited by 141
“Others have suggested that vector delivery into the lateral ventricles, a common clinical procedure, results in effective vector distribution.(14) It has also been reported that delivery via lumbar puncture can be improved by placing animals in the Trendelenburg position after injection to promote cranial vector distr…”
BackgroundResultGene therapy for neurodegenerative diseases
O’Connor, D. M., & Boulis, N. M. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.06.001 · Cited by 148
Hinderer, C., Bell, P., Vite, C. H., Louboutin, J.-P., Grant, R., Bote, E., Yu, H., Pukenas, B., Hurst, R., & Wilson, J. M. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.51 · Cited by 129
Bey, K., Deniaud, J., Dubreil, L., Joussemet, B., Cristini, J., Ciron, C., Hordeaux, J., Le Boulc’h, M., Marche, K., Maquigneau, M., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.04.001 · Cited by 116
“The ICV route was previously used in a large animal model for AAV delivery into the CNS, demonstrating therapeutic benefits and a good safety profile.(29) However, to our knowledge, no groups have developed ICV delivery in NHPs.”
Clinical Gene Therapy for Neurodegenerative Diseases: Past, Present, and Future
Piguet, F., Alves, S., & Cartier, N. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.160 · Cited by 109
“Intraparenchymal injection of limited doses of vectors is likely limited compared to high vector dose and systemic delivery.(12) Certain serotypes of AAV also have the potential ability to cross the BBB and enter the CNS, making AAV vectors attractive tools for the therapy of neurodegenerative diseases.”
Methods for Gene Transfer to the Central Nervous System
Kantor, B., Bailey, R. M., Wimberly, K., Kalburgi, S. N., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00003-2 · Cited by 109
“Overall, multiple groups have now shown that intra-CSF delivery of AAV9 vectors results in widespread expression of transgenes in large animals and support the use of intra-CSF AAV9 vector delivery for gene therapy in humans (Haurigot et al., 2013).”
BackgroundIntrathecal Gene Therapy Corrects CNS Pathology in a Feline Model of Mucopolysaccharidosis I
Hinderer, C., Bell, P., Gurda, B. L., Wang, Q., Louboutin, J.-P., Zhu, Y., Bagel, J., O'Donnell, P., Sikora, T., Ruane, T., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.135 · Cited by 108
Weismann, C. M., Ferreira, J., Keeler, A. M., Su, Q., Qui, L., Shaffer, S. A., Xu, Z., Gao, G., & Sena-Esteves, M. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv168 · Cited by 105
Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions
Basner-Tschakarjan, E., & Mingozzi, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00350 · Cited by 95
“While these results strongly support the safety of gene transfer to eye and brain, future studies will help to understand whether the immune privilege is maintained at all vector doses, especially given the fact that some AAV vector serotypes can escape the blood–brain barrier (103), thus resulting in systemic exposur…”
ResultSelf-citationAdeno-Associated Virus Gene Therapy in a Sheep Model of Tay–Sachs Disease
Gray-Edwards, H. L., Randle, A. N., Maitland, S. A., Benatti, H. R., Hubbard, S. M., Canning, P. F., Vogel, M. B., Brunson, B. L., Hwang, M., Ellis, L. E., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.163 · Cited by 96
Jimenez, V., Muñoz, S., Casana, E., Mallol, C., Elias, I., Jambrina, C., Ribera, A., Ferre, T., Franckhauser, S., & Bosch, F. (2013) · Diabetes · doi:10.2337/db13-0311 · Cited by 88
“Conversely, the mini/aP2 promoter precluded transduction of the heart, and AAV8 and AAV9 vectors did not mediate genetic engineering of macrophages, consistent with the poor tropism of these serotypes for this cell type (35,49).”
BackgroundSelf-citationNatural history of Sanfilippo syndrome type A
Buhrman, D. Z., Thakkar, K., Poe, M. D., & Escolar, M. L. (2013) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-013-9661-8 · Cited by 92
Xiao, X., Guo, P., Prasadan, K. L., Shiota, C., Peirish, L., Fischbach, S., Song, Z., Gaffar, I. M., Wiersch, J. C., El‐Gohary, Y., et al. (2014) · Nature Protocols · doi:10.1038/nprot.2014.183 · Cited by 89
Advances in Diagnostic and Treatment Modalities for Intracranial Tumors
Dickinson, P. J. (2014) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.12370 · Cited by 89
Bradbury, A. M., Rafi, M., Bagel, J. H., Brisson, B. K., Marshall, M. S., Pesayco, J. P., Jiang, X., Swain, G. P., Prociuk, M. L., O’Donnell, P. A., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.151 · Cited by 88
“It has previously been shown in studies evaluating AAV gene therapy in a canine model of MPSIIIA and a feline model of Sandhoff disease that the use of species-specific transgenes decreases immunogenicity and increases long-term transgene expression.(28,29) One GLD dog was treated with AAVrh10 expressing human GALC by…”
ResultGolebiowski, D., van der Bom, I. M. J., Kwon, C.-S., Miller, A. D., Petrosky, K., Bradbury, A. M., Maitland, S., Kühn, A. L., Bishop, N., Curran, E., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.109 · Cited by 87
“The most effective gene therapy approaches based on intracranial infusion of AAV vectors have targeted structures highly interconnected with other regions of the brain such as the striatum, ventral tegmental area,(20) deep cerebellar nuclei (DCN),(21) thalamus,(22) or CSF.(8,23,24) These intracranial delivery strategi…”
BackgroundMitchell, N. L., Russell, K. N., Wellby, M. P., Wicky, H. E., Schoderboeck, L., Barrell, G. K., Melzer, T. R., Gray, S. J., Hughes, S. M., & Palmer, D. N. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.015 · Cited by 90
“-only bilateral injections consequent to the success of this delivery route in other large animal studies.(30,31)”
BackgroundSevigny, J., Uspenskaya, O., Heckman, L. D., Wong, L. C., Hatch, D. A., Tewari, A., Vandenberghe, R. R., Irwin, D. J., Saracino, D., Ber, I. L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02973-0 · Cited by 90
Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments
Sawamoto, K., Stapleton, M., Alméciga-Díaz, C. J., Espejo-Mojica, A. J., Losada, J. C., Súarez, D. A., & Tomatsu, S. (2019) · Drugs · doi:10.1007/s40265-019-01147-4 · Cited by 88
Neonatal systemic AAV induces tolerance to CNS gene therapy in MPS I dogs and nonhuman primates
Hinderer, C., Bell, P., Louboutin, J.-P., Zhu, Y., Yu, H., Lin, G., Choa, R., Gurda, B. L., Bagel, J., O'Donnell, P., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.99 · Cited by 85
Efficient Gene Transfer to the Central Nervous System by Single-Stranded Anc80L65
Hudry, E., Andres-Mateos, E., Lerner, E. P., Volak, A., Cohen, O., Hyman, B. T., Maguire, C. A., & Vandenberghe, L. H. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.07.006 · Cited by 84
Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques
Borel, F., Gernoux, G., Sun, H., Stock, R., Blackwood, M., Brown, R. H., & Mueller, C. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aau6414 · Cited by 78
Liver induced transgene tolerance with AAV vectors
Keeler, G. D., Markusic, D. M., & Hoffman, B. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.002 · Cited by 81
Hordeaux, J., Hinderer, C., Goode, T., Buza, E. L., Bell, P., Calcedo, R., Richman, L. K., & Wilson, J. M. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.06.004 · Cited by 81
“This is likely due to asymmetric distribution of NAbs between the systemic and CNS compartments observed by us and others.(24,25) The fact that DRG transduction was also not impacted suggests that AAV particles gained entry via the CSF rather than the fenestrated endothelium of the DRG.”
BackgroundPrasad, S., Dimmock, D. P., Greenberg, B., Walia, J. S., Sadhu, C., Tavakkoli, F., & Lipshutz, G. S. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.138 · Cited by 81
Chowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 82
Treatment of brain disease in the mucopolysaccharidoses
Scarpa, M., Orchard, P. J., Schulz, A., Dickson, P., Haskins, M. E., Escolar, M. L., & Giugliani, R. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2017.10.007 · Cited by 84
“This immune response could be avoided by immunosuppression or immunomodulation [78,83,85,95,99,100].”
Hordeaux, J., Hinderer, C., Buza, E. L., Louboutin, J.-P., Jahan, T., Bell, P., Chichester, J. A., Tarantal, A. F., & Wilson, J. M. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.012 · Cited by 76
“This immune response may have been enhanced by the use of a xenoantigen, as was previously reported in the context of other storage diseases.(40) The impact of circulating antibodies on the efficacy of gene therapy is unknown.”
ResultMcCurdy, V. J., Rockwell, H. E., Arthur, J. R., Bradbury, A. M., Johnson, A. K., Randle, A. N., Brunson, B. L., Hwang, M., Gray‐Edwards, H. L., Morrison, N. E., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.108 · Cited by 82
Clinical Applications Involving CNS Gene Transfer
Kantor, B., McCown, T., Leone, P., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00002-0 · Cited by 74
“Similar results could be achieved at a lower dose if the vector was injected into the CSF of the cisterna magna, and the approach translated to canines (Haurigot et al., 2013).”
BackgroundResultAdeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
Hughes, M. P., Smith, D. A., Morris, L., Fletcher, C., Colaço, A., Huebecker, M., Tordo, J., Palomar, N., Massaro, G., Henckaerts, E., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy212 · Cited by 74
“istration (33) and AAV9-mediated synapsin promoter activity within the liver (34) have previously been described.”
BackgroundWhittemore, K., Derevyanko, A., Martinez, P., Serrano, R., Pumarola, M., Bosch, F., & Blasco, M. A. (2019) · Aging · doi:10.18632/aging.101982 · Cited by 69
Self-citationSustained Normalization of Neurological Disease after Intracranial Gene Therapy in a Feline Model
McCurdy, V. J., Johnson, A. K., Gray-Edwards, H. L., Randle, A. N., Brunson, B. L., Morrison, N. E., Salibi, N., Johnson, J. A., Hwang, M., Beyers, R. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007733 · Cited by 71
“One cat that was symptomatic at the time of surgery (8-1626) has moderately progressive disease at 29.”
InfluentialNovel therapies for mucopolysaccharidosis type III
Yılmaz, B. Ş., Davison, J. E., Jones, S. A., & Baruteau, J. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12316 · Cited by 71
“High-titre serum anti-AAV9 antibodies only partially blocked CSF-mediated gene transfer to the dog brain.(130) Anti-AAV antibody titres were reported lower in CSF than in serum samples of healthy and MPS IIIA children.”
BackgroundMethodInfluentialGene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development
Massaro, G., Geard, A. F., Liu, W., Coombe-Tennant, O., Waddington, S. N., Baruteau, J., Gissen, P., & Rahim, A. A. (2021) · Biomolecules · doi:10.3390/biom11040611 · Cited by 68
Ye, D., Chukwu, C., Yang, Y., Hu, Z., & Chen, H. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115363 · Cited by 68
Lysosomal storage disease: Gene therapy on both sides of the blood–brain barrier
Aronovich, E. L., & Hackett, P. B. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.09.011 · Cited by 69
“Therapeutic effect using AAV9 has been demonstrated in mice [76,79,83], cats [78,82,86], dogs [78,87–89], pigs [90] and non-human primates [35,83,91,92].”
BackgroundMethodInfluentialMotas, S., Haurigot, V., Garcia, M., Marcó, S., Ribera, A., Roca, C., Sánchez, X., Sánchez, V., Molas, M., Bertolin, J., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.86696 · Cited by 70
Self-citationSanfilippo Syndrome: Molecular Basis, Disease Models and Therapeutic Approaches
Benetó, N., Vilageliu, L., Grinberg, D., & Canals, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217819 · Cited by 66
“In another study performed in our lab, the use of shRNAs to downregulate EXTL2 and EXTL3 genes was found to reduce the GAG synthesis and storage in MPS IIIA fibroblasts.”
BackgroundResultInfluentialStrategies to circumvent humoral immunity to adeno-associated viral vectors
Tse, L. V., Moller-Tank, S., & Asokan, A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1035645 · Cited by 61
“At least one study has shown that cerebrospinal fluid (CSF) may carry less NAbs, when compared with serum and intra-CSF administration of rAAV9 in dogs is not completely affected by pre-existing-NAbs [32].”
BackgroundLong-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease
Hordeaux, J., Dubreil, L., Robveille, C., Deniaud, J., Pascal, Q., Dequéant, B., Pailloux, J., Lagalice, L., Ledevin, M., Babarit, C., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0464-2 · Cited by 59
“The feasibility of AAV-mediated gene transfer via the CSF in large animal models and non-human primates has been largely demonstrated by we [3, 4], and others [19, 25, 27, 28, 41, 42, 49, 50].”
BackgroundMethodArmbruster, N., Lattanzi, A., Jeavons, M., Van Wittenberghe, L., Gjata, B., Marais, T., Martin, S., Vignaud, A., Voit, T., Mavilio, F., et al. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.60 · Cited by 54
Amado, D. A., Rieders, J. M., Diatta, F., Hernandez-Con, P., Singer, A., Mak, J. T., Zhang, J., Lancaster, E., Davidson, B. L., & Chen-Plotkin, A. S. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.013 · Cited by 58
“We selected AAV serotype 9 (AAV9) based on its ability to broadly disperse and infect neurons and glia after CSF delivery, as well as its prior track record.(28,34,39) We also tested AAV serotype 4 (AAV4), due to its ependymal selectivity and safety profile,(30,40,41) to maximize CSF secretion with the goal of broad C…”
MethodTranslational Feasibility of Lumbar Puncture for Intrathecal AAV Administration
Hinderer, C. J., Katz, N., Dyer, C., Goode, T. L., Johansson, J., Bell, P. L., Richman, L. K., Buza, E. L., & Wilson, J. M. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.04.012 · Cited by 57
Lattanzi, A., Salvagno, C., Maderna, C., Benedicenti, F., Morena, F., Kulik, W., Naldini, L., Montini, E., Martino, S., & Gritti, A. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu034 · Cited by 60
“Similar considerations might apply to a novel GT approach based on direct CSF administration of AAV9 that has recently been reported as highly effective in treating the central and somatic pathology of mucopolysaccaridosis IIIA mice (53).”
BackgroundDashkoff, J., Lerner, E. P., Truong, N., Klickstein, J. A., Fan, Z., Mu, D., Maguire, C. A., Hyman, B. T., & Hudry, E. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.81 · Cited by 56
Adeno-Associated Virus Vector for Central Nervous System Gene Therapy
Zhu, D., Schieferecke, A. J., Lopez, P. A., & Schaffer, D. V. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.03.010 · Cited by 56
Dog as a model in studies on human hereditary diseases and their gene therapy
Switonski, M. (2014) · Reproductive Biology · doi:10.1016/j.repbio.2013.12.007 · Cited by 56
Rockwell, H. E., McCurdy, V. J., Eaton, S. C., Wilson, D. U., Johnson, A. K., Randle, A. N., Bradbury, A. M., Gray-Edwards, H. L., Baker, H. J., Hudson, J. A., et al. (2015) · ASN Neuro · doi:10.1177/1759091415569908 · Cited by 56
“, 2014) and that lysosomal enzyme is distributed throughout the brain parenchyma after CSFmediated delivery of AAV (Liu et al., 2005; Haurigot et al., 2013).”
BackgroundRibera, A., Haurigot, V., Garcia, M., Marcó, S., Motas, S., Villacampa, P., Maggioni, L., León, X., Molas, M., Sánchez, V., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu727 · Cited by 53
“S9C), an organ known to be refractory to cross-correction (18,25,26,50,55).”
BackgroundSelf-citationIntravenous AAV9 efficiently transduces myenteric neurons in neonate and juvenile mice
Gombash, S. E., Cowley, C. J., Fitzgerald, J. A., Hall, J. C. E., Mueller, C., Christofi, F. L., & Foust, K. D. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00081 · Cited by 54
“…identification of adeno-associated viral vector (AAV) serotypes that cross the blood brain barrier (BBB) resulted in unprecedented therapeutic benefit in animal models of neurological disease (Foust et al., 2010, 2013; Fu et al., 2011; Ahmed et al., 2013; Garg et al., 2013; Haurigot et al., 2013).”
BackgroundGene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches
Fraldi, A., Serafini, M., Sorrentino, N. C., Gentner, B., Aiuti, A., & Bernardo, M. E. (2018) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-018-0565-y · Cited by 57
Enzyme replacement therapy and beyond—in memoriam Roscoe O. Brady, M.D. (1923–2016)
Ries, M. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0032-8 · Cited by 56
“In addition, it would be desirable to have robust and unfragmented long-term outcome data for treatment in order to assess the potential for further innovation more thoroughly (Hollak et al 2011).”
BackgroundRoca, C., Motas, S., Marcó, S., Ribera, A., Sánchez, V., Sánchez, X., Bertolin, J., León, X., Pérez, J., Garcia, M., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx058 · Cited by 59
“An additional advantage of intra-CSF delivery over intravenous infusion is that transduction is not limited by anti-AAV seropositivity because the BBB maintains the concentration of immunoglobulins in the CSF very low, even in seropositive patients with advanced MPS disease (22).”
BackgroundMethodResultSelf-citationEmerging drugs for the treatment of mucopolysaccharidoses
Giugliani, R., Federhen, A., Vairo, F. P. E., Vanzella, C., Pasqualim, G., da Silva, L. M. R., Giugliani, L., de Boer, A. P. K., de Souza, C. F. M., Matte, Ú. D. S., et al. (2016) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2016.1123690 · Cited by 53
“5 mg/Kg weekly [18] ● Intravenous ERT with idursulfase beta/Phase III clinical trial completed [21,22] ● Intravenous plus intrathecal ERT with idursulfase alfa/Phase II/III clinical trial [30(NCT02055118)] ● Intravenous ERT with recombinant IDS fused to a monoclonal antibody/ Phase I/II clinical trial [72] ● Gene ther…”
MethodHumoral immune responses to AAV gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52
“Similarly, intrathecal delivery of AAV to the CSF has been shown partially to circumvent pre-existing anti-AAV9NAbs (Haurigot et al., 2013), suggesting this mode of administration may be preferable to systemic administration of AAV9 for delivering genes to the CNS (Jackson, Dayton &Klein, 2015).”
InfluentialEfficacy and Safety of a Krabbe Disease Gene Therapy
Hordeaux, J., Jeffrey, B. A., Jian, J., Choudhury, G. R., Michalson, K. T., Mitchell, T. W., Buza, E. L., Chichester, J. A., Dyer, C., Bagel, J. H., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.245 · Cited by 55
Hordeaux, J., Dubreil, L., Deniaud, J., Iacobelli, F., Moreau, S., Ledevin, M., Guiner, C. L., Blouin, V., Duff, J. L., Mendes-Madeira, A., et al. (2015) · Gene Therapy · doi:10.1038/gt.2014.121 · Cited by 55
Gene therapy for lysosomal storage disorders: a good start
Biffi, A. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv457 · Cited by 54
“Most recent examples report on the favorable phenotypic outcome of AAV8 administration in MPSIIIA and B mice (86,87) and AAV2 in a dog model of late-infantile ceroid lipofuscinosis (LINCL) (in press).”
BackgroundRecent trends in mucopolysaccharidosis research
Kobayashi, H. (2018) · Journal of Human Genetics · doi:10.1038/s10038-018-0534-8 · Cited by 56
Karumuthil‐Melethil, S., Marshall, M. S., Heindel, C., Jakubauskas, B., Bongarzone, E. R., & Gray, S. J. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23882 · Cited by 51
“…for AAV9 has been confirmed in multiple laboratories to confer widespread gene transfer across the CNS, across multiple small and large animal models, including nonhuman primates (Samaranch et al., 2012; Haurigot et al., 2013; Gray et al., 2013; Bucher et al., 2013; Passini et al., 2014).”
BackgroundTruxal, K. V., Fu, H., McCarty, D. M., McNally, K. A., Kunkler, K. L., Zumberge, N. A., Martin, L. C., Aylward, S. C., Alfano, L. N., Berry, K., et al. (2016) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2016.08.002 · Cited by 52
An update on gene therapy for lysosomal storage disorders
Nagree, M. S., Scalia, S., McKillop, W. M., & Medin, J. A. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1607837 · Cited by 53
“For example, systemic injection of AAV9 serotyped vector leads to transduction of brain parenchymal cells, suggesting blood-brain barrier (BBB) crossover [63].”
BackgroundInfluentialIannitti, T., Scarrott, J. M., Likhite, S., Coldicott, I. R. P., Lewis, K. E., Heath, P. R., Higginbottom, A., Myszczynska, M. A., Milo, M., Hautbergue, G. M., et al. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.04.015 · Cited by 49
Delivering gene therapy for mucopolysaccharide diseases
Wood, S., & Bigger, B. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.965089 · Cited by 50
“These results were also repeated in a dog model (Haurigot et al., 2013).”
BackgroundResultChen, X., Dong, T., Hu, Y., Pace, R. D., Mattera, R., Eberhardt, K., Ziegler, M., Pirovolakis, T., Şahin, M., Bonifacino, J. S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164575 · Cited by 49
Chen, X., Dong, T., Hu, Y., Shaffo, F. C., Belur, N. R., Mazzulli, J. R., & Gray, S. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci146286 · Cited by 48
Laoharawee, K., Podetz-Pedersen, K. M., Nguyen, T. T. T. N., Evenstar, L. B., Kitto, K. F., Nan, Z., Fairbanks, C. A., Low, W. C., Kozarsky, K., & McIvor, R. S. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.184 · Cited by 48
Piguet, F., de Saint Denis, T., Audouard, E., Beccaria, K., André, A., Wurtz, G., Schatz, R., Alves, S., Sevin, C., Zerah, M., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.105 · Cited by 45
“Studies have been performed in dogs, 85,89,90 NHP, 13,84,91 pigs, 83,92 and marmosets 93 mainly using AAV9 or AAVrh10 vector in neonates (5 days old) or in adult animals (Table 3).”
Hinderer, C. J., Katz, N., Louboutin, J., Bell, P. L., Yu, H., Nayal, M., Kozarsky, K., O'Brien, W. T., Goode, T. L., & Wilson, J. M. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.101 · Cited by 48
“22,26 In the present study, ICV delivery of an AAV9 vector carrying the human IDS gene in MPS II mice resulted in therapeutic levels of expression in the CNS and resolution of brain storage lesions.”
Yamazaki, Y., Hirai, Y., Miyake, K., & Shimada, T. (2014) · Scientific Reports · doi:10.1038/srep05506 · Cited by 46
A Preclinical Study Evaluating AAVrh10-Based Gene Therapy for Sanfilippo Syndrome
Winner, L. K., Beard, H., Hassiotis, S., Lau, A. A., Luck, A. J., Hopwood, J. J., & Hemsley, K. M. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.170 · Cited by 43
“…involving intracerebroventricular administration of very high-dose AAV9-SGSH resulted in full-body correction of disease parameters in MPS IIIA mice 46 ; however, to achieve such favorable CNS results from intravenous delivery, significant systemic exposure to high doses of the vector is required,…”
Understanding and Tackling Immune Responses to Adeno-Associated Viral Vectors
Verdera, H. C., Unzu, C., Valeri, E., Adriouch, S., González‐Aseguinolaza, G., Mingozzi, F., & Kajaste‐Rudnitski, A. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.119 · Cited by 47
Self-citationKarumuthil-Melethil, S., Nagabhushan Kalburgi, S., Thompson, P., Tropak, M., Kaytor, M. D., Keimel, J. G., Mark, B. L., Mahuran, D., Walia, J. S., & Gray, S. J. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.013 · Cited by 43
Translating CRISPR-Cas Therapeutics: Approaches and Challenges
Tay, L. S., Palmer, N. D., Panwala, R., Chew, W. L., & Mali, P. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0025 · Cited by 47
“Intracerebrospinal fluid (CSF) delivery is also able to provide widespread distribution in the CNS and reduce transduction of periphery organs.(186,187) The third approach is to directly deliver to target regions, limiting therapy to the site of administration; hence, broader delivery will require multiple injections…”
Gougeon, M.-L., Poirier-Beaudouin, B., Ausseil, J., Zérah, M., Artaud, C., Heard, J.-M., Deiva, K., & Tardieu, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.655478 · Cited by 38
“In preclinical studies in MPS IIIB mice (8, 9) and dogs (10, 11), beneficial biochemical and neurological effects with intracerebral gene therapy administered”
BackgroundGene therapy for mitochondrial disorders
Keshavan, N., Minczuk, M. A., Viscomi, C. F., & Rahman, S. (2024) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12699 · Cited by 43
“Intracerebro-ventricular AAV9 injections showed excellent biodistribution throughout the brain, 133 including transduction of both neurons and glia.”
BackgroundMarcó, S., Haurigot, V., Jaén, M. L., Ribera, A., Sánchez, V., Molas, M., Garcia, M., León, X., Roca, C., Sánchez, X., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.017 · Cited by 45
“In a previous study, we observed that after delivery of AAV9 vectors to the CSF of dogs through either cisterna magna or lateral ventricle injection, the lumbosacral intumescence and the cauda equina were the sections of the spinal cord with the highest levels of transgene expression.(34) Hence, we focused on these re…”
BackgroundMethodInfluentialSelf-citationRoutes of administration for adeno-associated viruses carrying gene therapies for brain diseases
Zhou, K., Han, J., Wang, Y., Zhang, Y., & Zhu, C. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.988914 · Cited by 46
Bucher, T., Dubreil, L., Colle, M.-A., Maquigneau, M., Deniaud, J., Ledevin, M., Moullier, P., & Joussemet, B. (2014) · Gene Therapy · doi:10.1038/gt.2014.16 · Cited by 40
Metadata
- Authors
- Haurigot, V., Marcó, S., Ribera, A., Garcia, M., Ruzo, A., Villacampa, P., Ayuso, E., Añor, S., Andaluz, A., Pineda, M., García-Fructuoso, G., Molas, M., Maggioni, L., Muñoz, S., Motas, S., Ruberte, J., Mingozzi, F., Pumarola, M., & Bosch, F.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Children's Hospital of Philadelphia (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2013-07-01
- Volume
- 123
- Issue
- 8
- Pages
- 3254-3271
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3726158
- OpenAlex
- W2085717798
- Cited by
- 215
- References
- 69
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 27 · 2023: 9 · 2022: 15 · 2021: 16 · 2020: 17 · 2019: 13 · 2018: 27 · 2017: 16 · 2016: 17 · 2015: 17 · 2014: 28 · 2013: 5
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- Funders
- Fundación Ramón Areces
- Generalitat de Catalunya
- Ministerio de Ciencia e Innovación
- MPS España
- Universitat Autònoma de Barcelona
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- mucopolysaccharidosis type IIIA, lysosomal storage disease, AAV9, blood-brain barrier, heparan sulfate, glycosaminoglycan accumulation, intracerebroventricular administration, beagle dogs, mouse model
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.